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Abstract: Within our therapeutic drug arsenal, antibiotics are of significant importance and are widely
used in huge amounts to medicate, e.g., bacterial infections in humans and animals. Regarding the
more than 10 types of antimicrobial drugs, the highly important orally taken β-lactams typically
include dry suspension formulations. In many cases for this formulation, even after usage according
to specification, residues remain in the prepared dry suspension bottle, which is often cleaned at
home and the contents are flushed down into domestic wastewater. This plausible practice adds
to the fact that, e.g., amoxicillin can be found in river waters, and is to be monitored in the EU,
as given by resolution 2008/105/EG article 8b. When imported into the environment, β-lactam
antibiotics can cause severe ecological problems, and equally importantly, therapeutic applications
of these antibiotics are endangered by the forced development of pathogenic resistance. To avoid
these issues, we developed and validated a fast, simple, robust, and cost-effective method using a
1 M sodium hydroxide solution to effectively hydrolyze and inactivate β-lactam residues. In this
paper, we strongly propose a procedure involving pharmacists to take back residue of β-lactam dry
suspension formulations. Subsequently, qualified pharmaceutical staff could inactivate β-lactam
residue in the laboratory by the proposed method, and then dispose of the mixture into wastewater.
Keywords: β-lactam antibiotics; targeted hydrolysis; environmental benefit
1. Introduction
Anthropogenic pollution of the environment has recently gained increased public
interest and is triggering more and more concern [1,2]. Examples of bio-accumulative
pollutants include microplastics [3,4], toxic/synthetic chemicals [5], and drugs (pharma-
cologically highly active pharmaceutical ingredients, APIs) that can be detected in the
environment, even in remote areas [1,2]. APIs are actually used in therapeutic approaches
to treat human and animal diseases but can also cause severe collateral side effects when
such biologically highly active compounds survive wastewater cleanup and reach aquatic-
or ecosystems beyond [6,7]. Human and veterinary drugs are used in massive quantities
worldwide [8], and the effect of APIs and/or their metabolites after excretion into the
environment is, in most cases, not fully understood [9]. Suggested solutions to the complex
problem of persistent synthetic compounds such as APIs in the environment have already
been put forward, including approaches towards green chemistry [10], technological up-
grades of sewage water plants regarding photolytic and oxidative degradation [11], and
sociological approaches [12].
In general, the excretion via urine or feces from patients using intended dosage
schemes can be considered to be a major source of APIs and their metabolites in wastew-
ater [10]. Other pathways of pollution may include improper domestic disposal [13]
and from the industrial waste of API manufacturing plants [10]. However, most APIs
are specifically designed for optimal bioavailability and strong metabolic degradation
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resistance, and these can show significant persistence in the aquatic environment, thus
accumulating and yielding trace quantities in rivers, lakes, and even drinking water [14].
Prominent examples of environmentally critical APIs include endocrine disruptors such
as ethinylestradiol [15], the non-steroidal pain killer and antiphlogistic diclofenac [16],
the antiepileptic carbamazepine [17], and contrast agents such as iomeprol [18] used in
diagnostics (Scheme 1).
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Scheme 1. Chemical structures of prominent examples of environmentally critical APIs.
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levels [19]. These data co relate to t t t t, . ., i in Ger any, 6 metric tons of
antibiotics wer used for human therapy, and 742 metric tons f r veterinary use, of which,
in both cases, β-lactams accounted for the largest part (e.g., veterinary penicillins used to
treat livestock totaled 279 metric tons) [20].
The ecological relevance of critical PIs is e phasized by resolution 2008/105/EG
article 8b, a guideline for agencies to onitor ethinylestradiol, erythromycin, azithromycin,
ciprofloxacin, and amoxicillin (among other critical APIs) in ater syste s of the Eu-
ropean Union. However, while one might expect that the highly metabolic resistant
ciprofloxacin [21] can be detected in water samples [22], to our surprise, the relatively
metabolically and chemically reactive β-lactam antibiotic amoxicillin [23] can also be de-
tected at high concentrations in river waters [24]. Obviously, amoxicillin is widely used
against many bacterial infections and, additionally, it is administered in high dosages
(e.g., more than 3000 mg/adult patient daily). Consequently, it is troubling to find such
high amounts of amoxicillin in river waters, suggesting significant deposition pathways
into the aquatic environment [25,26]. When considering plausible sources, a fraction of
therapeutically employed amoxicillin could be excreted non-metabolized from patients, as
outlined above [27]. This entry path requires the amoxicillin/β-lactam antibiotic to appar-
ently survive, at least partially [28], the harsh biodegradation processes in sewage water
treatment plants [19]. Secondly, raw wastewater may not have been treated sufficiently [29].
In line with this notion, amoxicillin originating from veterinary approaches [30] is more
likely to make its way directly into water systems without passing through any sewage
water treatment [31]. Furthermore, we hypothesize an alternative amoxicillin/β-lactam
source for pollution since, in the vast majority of European countries (as well as in other
developed countries), pharmaceutical waste must be returned to community pharmacies.
Water 2021, 13, 2225 3 of 10
Specialized companies manage the collected pharmaceutical waste. In spite of this, it is
apparent that antibiotics are found in water effluents.
Residue of β-Lactam Dry Suspension Formulation as a Potential Source of Pollution
For amoxicillin and further β-lactam antibiotics, a unique dosage situation applies,
especially for children. From a pharmaceutical and technological point of view, in addition
to classic, rather large β-lactam API-containing tablets, amoxicillin is often marketed
in special taste-masked, dry suspension formulations suitable mainly for the treatment
of infections in pediatrics [32]. Commercial dry suspension formulations come as dry
mixtures that, prior to usage, require the addition of water, yielding a suspension, which is
ready for about 2 weeks of usage when stored in the fridge [33]. Regarding this particularly
convenient dosage form, the total amount of amoxicillin (and other β-lactam antibiotics
respectively) in the prepared bottle covers a wide range of dosage correlating with the
body weight of small children up to that of teens or adults. Typically, even after application
according to specification, e.g., for smaller children, a significant residue of the prepared
suspension remains in the bottle. Finally, after a relatively short therapy, this residue may
then be cleaned at home and the content flushed down into domestic wastewater [34],
whereas the empty bottle is disposed of as glass waste. A similar scenario could be true for
procedures in hospitals [35].
In some cases, the package instructions of dry suspension pharmaceuticals advise
asking a pharmacist how to proceed regarding the disposal of the remaining formulation,
but without giving any details about professional waste management. Accordingly, to the
best of our knowledge, there is no general guideline for pharmacists regarding how to
handle such dry suspension remains. The rinsing of prepared dry suspension bottles after
therapeutic usage, may quite plausibly contribute to the fact that amoxicillin, as well as
other β-lactams (and potentially additional APIs from liquid formulations), are present in
high concentrations in river waters. In addition to antibiotics potentially causing severe eco-
logical issues in general [36], a forced development of striking bacterial resistance [37] may
occur, thus diminishing their highly valuable antibiotic efficacy for future applications [38].
2. Materials and Methods
2.1. Reactivity of β-Lactams towards Hydrolysis
The molecular mechanism of action of β-lactam antibiotics, including penicillins,
cephalosporins, and β-lactamase inhibitors, typically involves a nucleophilic attack from a
catalytic serine residue within the active site of penicillin-binding proteins (PBPs such as
transpeptidases) [39]. The reaction leads to ring opening of the β-lactam and thus pseudo-
irreversible covalent acylation of the target protein (Figure 1A). Likewise, in addition to
the required electrophilic properties of the β-lactam carbonyl atom, this pharmacophore
“warhead” is highly susceptible also to, e.g., hydroxylamine or hydroxide ions [27]. The
alkaline hydrolytic reaction leads to immediate β-lactam ring opening and degradation
towards penicillic acid derivatives, and subsequently towards a variety of further products,
all inactive against bacteria due to the missing key β-lactam moiety (Figure 1B) [39]. The
unwanted reactivity of β-lactam antibiotics in an alkaline environment is the subject of
studies [40] typically performed by the pharmaceutical industry in the context of quality
control activities to assess API stability [41].
2.2. Targeted Hydrolysis of the β-Lactam Ring
In contrast to these stability applications, we aimed to exploit alkaline conditions
for the targeted quantitative hydrolysis of β-lactam dry suspension residue. Given a
potentially relatively quick hydrolysis and thus pharmacological inactivation of the β-
lactam ring [23], we set out to develop a fast, robust, cost-effective, and suitable method
for the alkaline degradation of amoxicillin and other β-lactam antibiotic dry suspension
residues. In order to demonstrate the efficacy of the method, we performed analytical
studies on the sodium hydroxide mediated hydrolysis of four different β-lactam antibiotic
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APIs commonly marketed as dry suspensions, namely amoxicillin, cefaclor, cefadroxil, and
cefuroxime (Scheme 2). It is significant that, for analytical purposes, both the pure APIs
and their prepared dry suspension formulations, respectively, were stirred with 1 M NaOH
solution at room temperature and the progress of the hydrolytic reaction was monitored
by HPLC and LC/MS analysis (n = 6 for validation; n = 3 for hydrolysis experiments; for
details see Supplementary Materials). As a suitable endpoint for the reaction, we defined
the time point at which the quantitative hydrolyzation, and thus 100% degradation of
the β-lactam, occurred. A more detailed kinetics of the alkaline hydrolyzation has been
reported elsewhere [42].
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Scheme 2. Chemical structures of the four β-lactam antibiotic APIs investigated in this study.
The dilution solution of amoxicillin was prepared from 20.0 mg paracetamol and
2.5 mL acetic acid in 197.5 mL filtered and distilled water. For diluting the cefaclor probes,
a solution of 20.0 mg paracetamol and 308 mg ammonium acetate was diluted in 4 mL
acetonitrile and 169 mL bidistilled water. By adding acetic acid dropwise to the solution,
a pH value of 4 was obtained. For cefadroxil and cefuroxime, the same dilution solution
was used, and consisted of, 20.0 mg paracetamol and 308 mg ammonium acetate in 10 mL
acetonitrile and 190 mL filtered and bidistilled water. The pH was adjusted to pH 5 by
adding acetic acid dropwise.
2.3. Preparation of HPLC Samples
The amoxicillin and cefaclor probes were prepared by adding 1.0 mL of the alkaline
dry suspension reaction mixture to 9.0 mL of the dilution solution. After mixing, the
solution was filtered through a LLG filter. The cef droxil n cefuroxime probes wer
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prepared by adding 0.2 mL of the alkaline dry suspension reaction mixture to 10.0 mL of
the dilution solution. The probe was then mixed and filtered through an LLG filter.
3. Results
In preliminary tests, we identified 1 M NaOH solution to be effective for the hydrol-
ysis of all four investigated β-lactam APIs. Adding 1 M NaOH to the same volume of
the respective prepared dry suspension formulation and stirring the mixture overnight
at ambient temperature accounted for a sufficient method. Consequently, all β-lactams
were quantitatively destroyed, yielding a mixture of polar degradation products. A more
detailed analysis of the reaction kinetics actually showed quite a fast hydrolysis of the
commonly used amoxicillin (Figure 2), cefaclor (Figure 3), and cefadroxil (see Supplemen-
tary Materials). In contrast, cefuroxime (see Supplementary Materials) turned out to be
the most stable compound in these conditions. However, in order to also reach a robust
and quantitative hydrolysis for cefuroxime, stirring a mixture of 2 parts of 1 M NaOH and
1 part of cefuroxime suspension formulation was effective in fully degrading cefuroxime
within 240 min (Table 1).






























Figure 2. (A). Reference HPLC chromatogram of prepared dry suspension of amoxicillin (AMX) with
paracetamol as internal standard (int.std.). Retention times rt AMX = 7.4 min, rt int. std. = 11.0 min.
(B). Sample mixture of AMX and int.std. was stirred for 20 min with the same volume of 0.5 M
NaOH, which quantitatively hydrolyzed AMX, yielding penicillo acid derivate of amoxicillin as the
main degradation product (deg. prod., rt = 6.3 min; rt int. std. = 11.0 min). LC/MS analysis of the
degradation products can be found in the Supplementary Materials.
Key parameters for quantitative alkaline hydrolyzation reactions of the four β-lactam
APIs are summarized in Table 2. An additional experiment employing the conditions
used for the more robust cefuroxime, but subsequently applied to the mixture of all four
combined dry suspension formulations, proved to quantitatively hydrolyze all β-lactam
APIs. Thus, as a robust and effective method to destroy the β-lactam APIs, we propose
to stir the collected suspension residue with twice the volume of 1 M NaOH at room
temperature for at least 240 min.
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Figure 3. (A). Reference HPLC chromatogram of prepared dry suspension of cefaclor (CfCl) with paracetamol as internal
standard (int.std.). Further method details can be found in the SI. Retention times rt CfCl = 26.1 min, rt int. std. = 17.5 min.
(B). Sample mixture of CfCl and int.std. was stirred for 20 min with the same volume of 0.4 M NaOH, which quantitatively
hydrolyzed cefaclor. LC/MS analysis of the degradation products can be found in the Supplementary Materials.
Table 1. Parameters for the alkaline hydrolyzation of the prepared cefuroxime β-lactam dry
suspension formulation. For each time point, three independent experiments were performed.









60 0.5 1:1 93.6 0.21
60 1.0 1:1 94.9 0.44
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60 1.0 2:1 95.5 0.92
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Table 2. Para eters for quantitative alkaline hydrolyzation of prepared β-lacta dry suspension
f l ti s. r I, i i , i l i l
.
API c NaOH [mol/L] Ratio NaOH/PreparedDry Suspension
100% β-Lactam
Hydrolysis Re ched at
amoxicillin 0.5 1:1 20 min
cefaclor 0.4 1:1 20 min
cefadroxil 1 2:1 60 min
cefuroxime 1 2:1 240 min
Water 2021, 13, 2225 7 of 10
4. Discussion and Conclusions
Therapeutically highly relevantβ-lactams, such as amoxicillin and several cephalosporins,
account for the most antibiotic usage in humans and, in particular, for the treatment of
infections in children [43]. Thus, for future applications, it is necessary to keep the therapeu-
tic efficacy of this long-used class of antibiotic. In line with this notion, it has been reported
that only a few new antibiotic compounds or classes are currently being developed by the
pharmaceutical industry [44]. Therefore, to help maintain the therapeutic effect of current
β-lactam antibiotics, in this study, we provide evidence for a fast, simple, robust, and
economic method for inactivating β-lactam residue from dry suspension formulations. The
procedure could be used to effectively avoid environmental contamination by β-lactam
antibiotics, adding further value by diminishing the potential for the development of
bacterial resistance. Among the general methods used in modern wastewater plants to
reduce the API load in the outlet [45], more specific methods were reported to tackle antibi-
otic residues. These include sophisticated electrochemical [46,47], photocatalytic [48–50],
absorption [51], and oxidative [52] techniques, and these could be useful for addressing
non-metabolized antibiotics subsequent to oral administration that are excreted by hu-
mans and animals. Obviously, these remedies cannot be easily addressed by the alkaline
hydrolysis reported herein. However, our cost-effective method could help to avoid the
introduction of β-lactams coming from the part of antibiotics contained in dry suspension
formulation residue. Thus, the method could be helpful in reducing their total entry load
into wastewaters.
To sum up, we researched β-lactams typically used for dry suspension formulations
and thus investigated four common β-lactam APIs and their respective dosage forms
regarding their susceptibility to alkaline hydrolysis. When adding twice the volume of
a 1 M NaOH solution to the remaining suspension formulation at ambient temperature,
our analysis showed a fast hydrolysis of the four relevant β-lactam antibiotics within a
240 min reaction time, resulting in a mixture of polar degradation products. A valid alkaline
hydrolysis and degradation of the combined dry suspension formulation residue containing
the most used β-lactam APIs amoxicillin, cefaclor, cefadroxil, and cefuroxime can be
achieved. Thus, this method is considered to be highly suitable for practical use regarding
laboratories in pharmacies and in clinics. Furthermore, the proposed hydrolysis conditions
should be investigated further to test the degradation of other approved β-lactam (and
macrolide) suspension formulations in order to fully validate the described method.
In general, it is not acceptable to have a poor or even non-existent waste management
for APIs. In many developed countries, community pharmacies take back pharmaceutical
waste, and the disposal is then managed by specialized companies. However, a particular
situation applies to liquid formulations, which may often be disposed of into domestic
wastewater. An effective and comprehensive disposal system should be established for the
therapeutically and ecologically highly critical class of (β-lactam-) antibiotics present in dry
suspension residue; it is in our own human interest to achieve this. Conceptually, it would
be most effective to interfere early in the process of APIs, such as β-lactam antibiotics,
draining unintentionally into the environment [13]. Thus, the data of this study could
serve in the development of a future practice guideline, where pharmacists are involved
to take back un-used residue of β-lactam dry suspension formulations from patients
(clinic and public). Qualified pharmaceutical personnel could subsequently deactivate
β-lactams in the laboratory by the described method using 1 M sodium hydroxide solution
prior to rinsing the inactive mixture down the sink. A comparable process should be
discussed for the use of β-lactam APIs in veterinary settings, in which antibiotics are often
employed as pure substances; that is to say, without any formulation at all. The proposed
method for the degradation of antibiotic residue prior to disposal could contribute to
creating multiple benefits in order to significantly reduce the unwanted β-lactam load in
the environment. Likewise, the procedure could help to reduce the emergence of collateral
bacterial resistances against this highly needed class of effective antibiotics. Finally, given
the strong growth of pathogenic/bacterial resistance and—as a direct consequence thereof—
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the emergence of ineffective antibiotics, a responsible and suitable antibiotic API waste
management program should be the focus of any serious public health program.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/w13162225/s1, Further details for Materials & Methods, HPLC analysis of amoxicillin, cefaclor,
cefadroxil, cefuroxime, and validation parameters.
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